UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): June 13, 2012
Fuse Science, Inc.
(Exact name of registrant as specified in charter)
Nevada
(State or other jurisdiction of incorporation)
| 000-22991 | 87-0460247 | |
| (Commission File Number) | (IRS Employer Identification No.) |
6135 N.W. 167th Street, Suite E-21, Miami Lakes, Florida 33180
(Address of principal executive offices and zip code)
| (305) 503-3873 |
| (Registrant’s telephone number including area code) |
| Former Name or Former Address (If Changed Since Last Report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
As used in this Current Report on Form 8-K and unless otherwise indicated, the terms the “Company,” “Fuse,” “we,” “us,” and “our” refer to Fuse Science, Inc. and its subsidiaries, unless the context requires otherwise.
| Item 8.01. | Other Events. |
On June 13, 2012, the Company issued a press release reporting the preliminary results of a scientific study of its transdermal delivery technology. A copy of the press release is filed herewith as Exhibit 99.1.
| Item 9.01 | Financial Statements and Exhibits. |
| (c) | Exhibits |
| Exhibit No. | Description | |
| 99.1 | Press Release, dated June 13, 2012 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| FUSE SCIENCE, INC. | |||
| Date: June 13, 2012 | By: | /s/ Brian Tuffin | |
| Brian Tuffin, Chief Executive Officer | |||
| 2 |
Exhibit 99.1
Fuse Science Sets New Standard of Transdermal
Delivery with Groundbreaking Scientific Results
Miami Lakes, FL – June 13, 2012 – Fuse Science Inc. (OTCQB: DROP), (www.fusescience.com) is pleased to announce the results of a study that begins to indicate the significant capabilities that reside in their proprietary technology. A third-party study, which is being released today at www.fusescience.com, reveals unique and differentiated, transdermal delivery capabilities that the Company believes has the potential to significantly improve drug delivery and minimize side effects. The results of the study center around four basic principles that matter to everyone when it comes to nutrition, energy and pharmaceutical delivery options:
Speed – Fuse Science is the first to report the ability to deliver caffeine through the epidermis in less than 3 minutes in an In Vitro Study. This opens the door for a wide variety of acute delivery options transdermally, which will significantly improve medical treatment options. Imagine the transformation of the $2 billion dollar internal analgesic category from a pill that takes 30 minutes to an hour to help provide relief vs. a roll-on with “Powered By Fuse™” technology that begins to work in less than 3 minutes.
Variability – The Study indicates that our proprietary delivery technology can influence the amount of medications and nutrients delivered through the skin at varying rates. This will allow for pediatric and adult dosing, as well as the ability to introduce a wide variety of new treatment applications designed to improve medical care, health and beauty and anti-aging therapies.
Duration – The study reports the superior progressive delivery of caffeine that has not peaked at 2 hours vs current published data of oral consumption which peaks at 45-60 minutes and thereafter falls off. We believe that this sets the stage for Fuse Science to deliver therapeutic levels of medications and nutrients over longer periods of time, creating better health outcomes.
Functionality – Fuse Science delivery technology can take products that are currently in patch form like nicotine, birth control and lidocaine, as a few examples of many, and turn them into simple transdermal roll–ons that deliver the same or better results without the constraints and draw backs of wearing a patch.
“We believe that proof of concept demonstrated by the study will be a key enabler in our global licensing efforts, and it further documents superior capabilities that reside within our technology,” said Jeanne Hebert, Vice President of Marketing & Clinical Research. “It is our objective to leverage our technology, which we believe extends well beyond these initial findings, to redefine the standard of performance in many multi-billion dollar pharmaceutical and nutritional categories and improve the lives of people around the world.”
“Needless to say, we are very pleased with the results of this initial study,” said Brian Tuffin, CEO of Fuse Science Inc. “We have been very deliberate and calculated with every action we’ve taken as a company and this study provides the first of several significant steps we’re taking to fully commercialize our proprietary delivery technology. We anticipate announcing in the coming days and weeks, more successes in this area which began with the licensing of some of our transdermal technology to Mission Athletecare early this year.”
If you would like to understand what it means to be Powered By Fuse!™, log onto www.poweredbyfuse.com and enter promo code “GetPowered” and receive 10% your next Powered By Fuse™ Order.
About Fuse Science Inc.
Fuse Science Inc. (OTCQB: DROP), is an innovative consumer products holding company based in Miami Lakes, Florida. Fuse Science holds the rights to new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals. The company maintains the rights to sublingual and transdermal delivery systems for bioactive agents that can now, for the first time, effectively encapsulate and charge many varying molecules in order to produce complete product formulations which can bypass the gastrointestinal tract and enter the blood stream directly - all in a concentrated "DROP" form that is simply applied under the tongue. The Fuse Science technology is designed to accelerate conveyance of medicines or nutrients relative to traditional pills and liquids and can enhance how consumers receive these products. Information about Fuse Science is available online at www.fusescience.com and www.poweredbyfuse.com or by calling 305-503-FUSE (3873
| For more information: | To schedule an interview: |
| Fuse Science, Inc. | Gus DeQuesada |
| Investor Relations | Michelsen Advertising |
| Direct: (305) 503-3873, Ext. 2 | C-305-733-1410 / 786-488-7138 |
| Email: ir@fusescience.com | prnews@michelsenadvertising.com |
Safe Harbor Statement: Certain statements and information included in this release may constitute "forward-looking statements" as defined in the Federal Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied in such statements. Additional discussion of factors that could cause actual results to differ materially from management's projections, estimates and expectations is contained in the Company's SEC filings. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by federal securities laws.
# # #